PODD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. PODD is in a clear short-term downtrend (bearish MA stack and worsening MACD), has broken below the S1 support area, and there is no proprietary “buy-now” signal. While the stock is extremely oversold (RSI-6 ~11.8) and could bounce, the trend/price structure argues against chasing an entry before the chart stabilizes.
Trend is bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating persistent downside momentum. MACD histogram is -2.318 and negatively expanding, suggesting the selloff is still strengthening rather than basing. RSI_6 at 11.762 signals extreme oversold conditions (bounce risk), but oversold can persist in strong downtrends. Key levels: the stock (255.58) is below S1 (259.159) and closer to S2 (250.858); a failure to hold 250-251 increases downside risk. Upside recovery would first need to reclaim the pivot (272.596) to improve near-term structure.
Strong underlying business momentum in recent quarter (high revenue growth, expanding gross margin).
Many Wall Street firms still rate Buy/Outperform with targets well above the current price, implying perceived valuation dislocation after the selloff.
Event catalyst: QDEC 2025 earnings on 2026-02-18 (pre-market) could reset sentiment if results/guide are strong.
Pattern-based model suggests a favorable skew over the next week (+5.18% probability-weighted outcome cited).
Technical breakdown and accelerating downside momentum (bearish MA stack + worsening MACD) suggests sellers still control trend.
Price is below near support (S1), increasing risk of a continuation leg toward/through S2 (~250.86).
Options OI put/call > 1 indicates meaningful hedging/defensive positioning.
Analyst caution is rising at the margin: TD Cowen downgraded to Hold citing modest upside and narrowing competitive advantages vs peers; several firms recently trimmed price targets (even while staying positive).
Latest reported quarter: 2025/Q3. Revenue grew to $706.3M (+29.86% YoY), net income $87.6M (+13.03% YoY), EPS $1.24 (+14.81% YoY). Gross margin improved to 72.22% (+4.17% YoY). Overall: strong top-line growth with improving margins; profit/EPS growth remains positive but trails revenue growth (suggesting some operating investment/expense growth).
Recent trend: still broadly bullish, but with some moderation. Most firms maintain Buy/Outperform and targets remain substantially above $255.6 (e.g., Goldman Buy with lowered PT $365; Bernstein Outperform with lowered PT $380; Truist Buy with PTs in the $390–$412 range; Evercore initiated Outperform $370; Canaccord raised to $450). The key negative shift: TD Cowen downgraded to Hold with a $294 PT, arguing PODD’s advantages may narrow and upside is more modest from here. Wall Street pros: strong product/form factor, pharmacy access, multi-year growth runway and pipeline. Cons: competition/feature parity risk over time and reduced near-term upside after prior momentum, plus current tape/technical weakness.
